EMA Withdrawn: Dasatinib Accord (dasatinib) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA has withdrawn the Dasatinib Accord product (dasatinib) from Accord Healthcare S.L.U., applicable to precursor cell lymphoblastic leukemia-lymphoma and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myelogenous Chronic Bcr-abl Positive
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Dasatinib Accord (dasatinib)

Snippet

Status: Withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Accord Healthcare S.L.U.. Decision date: 08/06/2022